The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: Major contributors or essential homeostatic modulators?

Immunology Letters

Volumn 136, Issue 2, 2011, Pages 115-121

  Ahern, David J ^a   Brennan, Fionula M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Inflammation; Natural Killer cell; Rheumatoid arthritis

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GAMMA INTERFERON; INTERLEUKIN 12; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN NKP80; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL INTERACTION; CLINICAL FEATURE; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE EXACERBATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; OSTEOCLASTOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS; TH17 CELL; TUMOR IMMUNITY;

EID: 79953047281     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.11.001     Document Type: Review

References (87)

1. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545.
2. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
3. Dalbeth N., Callan M. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002, 46:1763-1772.
4. negative phenotype. Rheumatology (Oxford) 2003, 42:870-878.
5. Flodstrom-Tullberg M., Bryceson Y.T., Shi F.D., Hoglund P., Ljunggren H.G. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009, 21:634-640.
6. Huntington N.D., Vosshenrich C.A., Di Santo J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007, 7:703-714.
7. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
8. Lanier L.L., Testi R., Bindl J., Phillips J.H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989, 169:2233-2238.
9. Ritz J., Schmidt R.E., Michon J., Hercend T., Schlossman S.F. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988, 42:181-211.
10. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
11. Lanier L.L., Le A.M., Civin C.I., Loken M.R., Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986, 136:4480-4486.
12. bright subset. Blood 2001, 97:3146-3151.
13. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
14. Voss S.D., Daley J., Ritz J., Robertson M.J. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol 1998, 160:1618-1626.
15. Ferlazzo G., Thomas D., Lin S.L., Goodman K., Morandi B., Muller W.A. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004, 172:1455-1462.
16. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990, 171:1509-1526.
17. Nagler A., Lanier L.L., Phillips J.H. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 1990, 171:1527-1533.
18. Matos M.E., Schnier G.S., Beecher M.S., Ashman L.K., William D.E., Caligiuri M.A. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993, 178:1079-1084.
19. Baume D.M., Robertson M.J., Levine H., Manley T.J., Schow P.W., Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 1992, 22:1-6.
20. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001, 166:6477-6482.
21. dim natural killer cell subsets. J Immunol 1998, 161:400-408.
22. Walzer T., Chiossone L., Chaix J., Calver A., Carozzo C., Garrigue-Antar L. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007, 8:1337-1344.
23. dim NK cells upon activation. J Immunol 2007, 178:4947.
24. dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89.
25. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73.
26. Cheent K., Khakoo S.I. Natural killer cells: integrating diversity with function. Immunology 2009, 126:449-457.
27. Ljunggren H.G., Karre K. In search of the'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
28. Smith H.R.C., Heusel J.W., Mehta I.K., Kim S., Dorner B.G., Naidenko O.V. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci 2002, 99:8826.
29. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
30. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
31. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997, 7:739-751.
32. Gardiner C.M. Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int J Immunogenet 2008, 35:1-8.
33. + NK cell clones. Int Immunol 1999, 11:29-35.
34. Iizuka K., Naidenko O.V., Plougastel B.F., Fremont D.H., Yokoyama W.M. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003, 4:801-807.
35. Carlyle J.R., Jamieson A.M., Gasser S., Clingan C.S., Arase H., Raulet D.H. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004, 101:3527-3532.
36. Aldemir H., Prod'homme V., Dumaurier M.J., Retiere C., Poupon G., Cazareth J., et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005, 175:7791-7795.
37. Rosen D.B., Bettadapura J., Alsharifi M., Mathew P.A., Warren H.S., Lanier L.L. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005, 175:7796-7799.
38. Butcher S., Arney K.L., Cook G.P. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur J Immunol 1998, 28:3755-3762.
39. Grundemann C., Bauer M., Schweier O., von Oppen N., Lassing U., Saudan P., et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol 2006, 176:1311-1315.
40. Ito M., Maruyama T., Saito N., Koganei S., Yamamoto K., Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006, 203:289-295.
41. Nicoll G., Ni J., Liu D., Klenerman P., Munday J., Dubock S., et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 1999, 274:34089-34095.
42. Zhang J.Q., Nicoll G., Jones C., Crocker P.R. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem 2000, 275:22121-22126.
43. Avril T., Floyd H., Lopez F., Vivier E., Crocker P.R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9 CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004, 173:6841-6849.
44. Cantoni C., Bottino C., Augugliaro R., Morelli L., Marcenaro E., Castriconi R., et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 1999, 29:3148-3159.
45. Binstadt B.A., Brumbaugh K.M., Dick C.J., Scharenberg A.M., Williams B.L., Colonna M. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 1996, 5:629.
46. Burshtyn D.N., Scharenberg A.M., Wagtmann N., Rajagopalan S., Berrada K., Yi T. Recruitment of tyrosine phosphatase HCP (SHP-1) by the killer cell inhibitory receptor. Immunity 1996, 4:77.
47. Meyaard L., Adema G.J., Chang C., Woollatt E., Sutherland G.R., Lanier L.L. LAIR-1 a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997, 7:283-290.
48. Yusa S., Catina T.L., Campbell K.S. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol 2002, 168:5047-5057.
49. Treanor B., Lanigan P.M., Kumar S., Dunsby C., Munro I., Auksorius E., et al. Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses. J Cell Biol 2006, 174:153-161.
50. Eriksson M., Leitz G., Fallman E., Axner O., Ryan J.C., Nakamura M.C., et al. Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets. J Exp Med 1999, 190:1005-1012.
51. Tomasello E., Blery M., Vely F., Vivier E. Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells. Semin Immunol 2000, 12:139-147.
52. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727.
53. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
54. Chalupny N.J., Sutherland C.L., Lawrence W.A., Rein-Weston A., Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 2003, 305:129-135.
55. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999, 285:730-732.
56. Hayakawa Y., Kelly J.M., Westwood J.A., Darcy P.K., Diefenbach A., Raulet D., et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002, 169:5377-5381.
57. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
58. Salih H.R., Rammensee H.G., Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002, 169:4098-4102.
59. Olcese L., Cambiaggi A., Semenzato G., Bottino C., Moretta A., Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol 1997, 158:5083-5086.
60. Lee I.F., Qin H., Trudeau J., Dutz J., Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004, 172:937-942.
61. + T cells in a transfer model of colitis. J Immunol 1998, 161:3256-3261.
62. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997, 186:1677-1687.
63. Xu W., Fazekas G., Hara H., Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 163:24-30.
64. Setiady Y.Y., Pramoonjago P., Tung K.S. Requirements of NK cells and proinflammatory cytokines in T cell-dependent neonatal autoimmune ovarian disease triggered by immune complex. J Immunol 2004, 173:1051-1058.
65. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000, 1:245-251.
66. Lo C.K., Lam Q.L., Sun L., Wang S., Ko K.H., Xu H., et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum 2008, 58:2700-2711.
67. Soderstrom K., Stein E., Colmenero P., Purath U., Muller-Ladner U., de Matos C.T., et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci USA 2010, 107:13028-13033.
68. Yanagihara Y., Shiozawa K., Takai M., Kyogoku M., Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999, 118:131-136.
69. Munschauer F.E., Hartrich L.A., Stewart C.C., Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995, 62:177-181.
70. Erkeller-Yusel F., Hulstaart F., Hannet I., Isenberg D., Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1993, 2:227-231.
71. Walzer T., Blery M., Chaix J., Fuseri N., Chasson L., Robbins S.H., et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 2007, 104:3384-3389.
72. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002, 195:327-333.
73. Piccioli D., Sbrana S., Melandri E., Valiante N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002, 195:335.
74. Spaggiari G.M., Carosio R., Pende D., Marcenaro S., Rivera P., Zocchi M.R., et al. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol 2001, 31:1656-1665.
75. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351.
76. Pende D., Castriconi R., Romagnani P., Spaggiari G.M., Marcenaro S., Dondero A., et al. Expression of the DNAM-1 ligands Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006, 107:2030-2036.
77. Della Chiesa M., Vitale M., Carlomagno S., Ferlazzo G., Moretta L., Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol 2003, 33:1657-1666.
78. bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004, 173:6418-6426.
79. Chan A., Filer A., Parsonage G., Kollnberger S., Gundle R., Buckley C.D., et al. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum 2008, 58:707-717.
80. Aramaki T., Ida H., Izumi Y., Fujikawa K., Huang M., Arima K., et al. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 2009, 19:245-252.
81. Nedvetzki S., Sowinski S., Eagle R.A., Harris J., Vely F., Pende D. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007, 109:3776.
82. Rabinovich B.A., Li J., Shannon J., Hurren R., Chalupny J., Cosman D. Activated, but not resting T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003, 170:3572-3576.
83. Cerboni C., Zingoni A., Cippitelli M., Piccoli M., Frati L., Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 2007, 110:606-615.
84. + T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007, 26:593-604.
85. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze_koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62:2876-2885.
86. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
87. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.